Endonovo Therapeutics (ENDV) Enterprise Value (2016 - 2023)
Endonovo Therapeutics has reported Enterprise Value over the past 13 years, most recently at -$32602.0 for Q2 2023.
- Quarterly results put Enterprise Value at -$32602.0 for Q2 2023, changed N/A from a year ago — trailing twelve months through Jun 2023 was -$32602.0 (changed N/A YoY), and the annual figure for FY2022 was -$98.0, up 99.89%.
- Enterprise Value for Q2 2023 was -$32602.0 at Endonovo Therapeutics, down from -$10942.0 in the prior quarter.
- Over the last five years, Enterprise Value for ENDV hit a ceiling of -$98.0 in Q4 2022 and a floor of -$547530.0 in Q2 2019.
- Median Enterprise Value over the past 5 years was -$13420.0 (2020), compared with a mean of -$56871.5.
- Biggest five-year swings in Enterprise Value: plummeted 48198.88% in 2021 and later surged 99.89% in 2022.
- Endonovo Therapeutics' Enterprise Value stood at -$18893.0 in 2019, then grew by 28.97% to -$13420.0 in 2020, then crashed by 540.36% to -$85936.0 in 2021, then surged by 99.89% to -$98.0 in 2022, then tumbled by 33167.35% to -$32602.0 in 2023.
- The last three reported values for Enterprise Value were -$32602.0 (Q2 2023), -$10942.0 (Q1 2023), and -$98.0 (Q4 2022) per Business Quant data.